Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
J Cell Physiol. 2018 Aug;233(8):5613-5622. doi: 10.1002/jcp.26273. Epub 2018 Mar 1.
Toll like receptor (TLR) signaling is involved in activating innate and adaptive immune responses and plays a critical role in inflammation-induced diseases such as colorectal cancer (CRC). Dysregulation of this signaling pathway can result in disturbance of epithelial layer hemostasis, chronic inflammatory, excessive repair responses, and development of CRC. There is now substantial evidence for the benefit of targeting of this pathway in cancer treatment, and several agents have been approved, such as BCG (Bacillus Calmette Guérin), MPL (monophosphoryl lipid A) and imiquimod. This review summarizes the current knowledge about the different functions of TLRs on tumor cells and their application in cancer therapy with particular emphasis on recent preclinical and clinical research in treatment of CRC.
Toll 样受体 (TLR) 信号通路参与激活先天和适应性免疫反应，并在炎症诱导的疾病（如结直肠癌 (CRC)）中发挥关键作用。该信号通路的失调可导致上皮层止血紊乱、慢性炎症、过度修复反应和 CRC 的发展。目前有大量证据表明该通路在癌症治疗中的靶向作用有益，并且已经批准了几种药物，如卡介苗（BCG）、MPL（单磷酰脂质 A）和咪喹莫特。本文综述了 TLR 对肿瘤细胞的不同功能及其在癌症治疗中的应用的最新认识，特别强调了最近在 CRC 治疗中的临床前和临床研究。
